BioSpace News Archive

Dicerna Provides Initial Observations From PHYOX ™ 3 Trial of Nedosiran for Treatment of Primary Hyperoxaluria and an Update on Data Presentation Plan — Preliminary Interim Data Show Normalization or Near-Normalization of Oxalate Levels in First Subset of Four Patients — — Nedosiran Multidose Data to Be Presented at OxalEurope Meeting Now Rescheduled to June 16, 2020 —

Kleo Pharmaceuticals Inc announced today that it has entered into a research collaboration with South Korea -based Green Cross LabCell (GCLC),

Covalon Announces New Breakthrough Antimicrobial Technology Formulated to Kill The COVID-19 Virus

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today released a new video on its website showing the efficacy of its lead drug candidate Metablok in reducing neutrophil recruitment in a mouse model of lung inflammation. The new video can be viewed at the Arch Biopartners website here (click to view) .

Resverlogix Corp. announced its participation at the American College of Cardiology Scientific Sessions, together with the World Congress of Cardiology, presenting two virtual posters made available on demand via an eAbstracts System starting Saturday, March 28, 2020.

Key trials in Huntington’s disease and non-small cell lung cancer are near completion; company working with trial sites to assess delays and determine the most efficient path to topline data

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it had produced five COVID-19 vaccine candidates for testing in its preclinical models.

Company to Host Conference Call with National Co-Principal Investigators Today at 4:15 p.m. ET to Provide Study Updates

On Saturday, March 21, General Motors, approached Esys Automation, a JR Automation company, to help produce face masks to combat the COVID-19 outbreak.

MEI Pharma, Inc. announced that the U.S. Food and Drug Administration granted Fast Track designation to ME-401, MEI’s investigational selective oral inhibitor of phosphatidylinositol 3-kinase delta for the treatment of adult Patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.